NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Phase 2

Active, not recruiting

Conditions: Recurrent Adrenal Cortical Carcinoma
Recurrent Clear Cell Sarcoma of Soft Tissue
Recurrent Ewing Sarcoma
Recurrent Osteosarcoma
Recurrent Primary Malignant Central Nervous System Neoplasm
Recurrent Renal Cell Carcinoma
Refractory Malignant Solid Neoplasm
Refractory Wilms Tumor
Alveolar Soft Part Sarcoma
Central Nervous System Neoplasm

Interventions: Drug: Cabozantinib
Drug: Cabozantinib S-malate
Other: Pharmacological Study

First Posted Date: 2016-08-16

Last Posted Date: 2025-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 109

Registration Number: NCT02867592

Locations: 🇺🇸
UCSF Medical Center-Mission Bay, San Francisco, California, United States
🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸
Huron Medical Center PC, Port Huron, Michigan, United States

and more 139 locations

Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

Phase 1

Active, not recruiting

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Unresectable Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm

Interventions: Drug: Atezolizumab
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging

First Posted Date: 2016-08-11

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT02862275

Locations: 🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States

and more 6 locations

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

Phase 1

Terminated

Conditions: Esophageal Neoplasms
Lung Neoplasms
Mesothelioma
Thymus Neoplasms
Neoplasms, Germ Cell and Embryonal

Interventions: Drug: Mithramycin

First Posted Date: 2016-08-09

Last Posted Date: 2022-04-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT02859415

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Avelumab for People With Recurrent Respiratory Papillomatosis

Phase 2

Completed

Conditions: Recurrent Respiratory Papillomatosis
Juvenile Laryngeal Papilloma
Respiratory Papillomatosis
Laryngeal Papilloma, Recurrent
Human Papilloma Virus

Interventions: Drug: Avelumab

First Posted Date: 2016-08-09

Last Posted Date: 2021-11-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 13

Registration Number: NCT02859454

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Phase 1

Recruiting

Conditions: Cervical Intraepithelial Neoplasia
Vulvar Neoplasms
Papillomavirus Infections
Carcinoma In Situ
Vulvar Diseases

Interventions: Biological: E7 TCR cells
Drug: Aldesleukin
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2016-08-08

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 180

Registration Number: NCT02858310

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Natural History of and Specimen Banking for People With Tumors of the Central Nervous System

Active, not recruiting

Conditions: Brain Cancer
Spine Tumor
Spine Cancer
Neoplasm
Brain Tumor

Interventions: Other: No Treatment

First Posted Date: 2016-08-02

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1214

Registration Number: NCT02851706

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Phase 2

Active, not recruiting

Conditions: Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Locally Advanced Unresectable Breast Carcinoma
Metastatic Breast Carcinoma

Interventions: Procedure: Biopsy Procedure
Drug: Atezolizumab
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Bone Scan
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Olaparib
Procedure: Positron Emission Tomography
Other: Questionnaire Administration
Procedure: X-Ray Imaging

First Posted Date: 2016-07-29

Last Posted Date: 2025-04-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 81

Registration Number: NCT02849496

Locations: 🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

and more 55 locations

Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Phase 2

Completed

Conditions: Recurrent Bladder Urothelial Carcinoma
Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7
Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7
Stage I Bladder Urothelial Carcinoma AJCC v6 and v7

Interventions: Drug: Atezolizumab

First Posted Date: 2016-07-26

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 172

Registration Number: NCT02844816

Locations: 🇺🇸
The University of Kansas Cancer Center - Olathe, Olathe, Kansas, United States
🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸
Southern Cancer Center PC-Daphne, Daphne, Alabama, United States

and more 269 locations

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2

Active, not recruiting

Conditions: Ovarian High Grade Serous Adenocarcinoma
Ovarian Seromucinous Carcinoma
Recurrent Fallopian Tube Clear Cell Adenocarcinoma
Recurrent Ovarian Carcinoma
Recurrent Ovarian Undifferentiated Carcinoma
Recurrent Platinum-Resistant Fallopian Tube Carcinoma
Fallopian Tube High Grade Serous Adenocarcinoma
Recurrent Fallopian Tube Endometrioid Adenocarcinoma
Recurrent Platinum-Resistant Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions: Drug: Atezolizumab
Procedure: Computed Tomography
Biological: Bevacizumab
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Other: Quality-of-Life Assessment

First Posted Date: 2016-07-21

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 444

Registration Number: NCT02839707

Locations: 🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States

and more 918 locations

Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma

Phase 2

Completed

Conditions: Cutaneous Neurofibroma
Neurofibromatosis Type 1
Optic Nerve Glioma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Selumetinib Sulfate

First Posted Date: 2016-07-21

Last Posted Date: 2023-12-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 11

Registration Number: NCT02839720

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Home Terms & Conditions Privacy Policy